A “leaked” conference article has revealed positive Phase I trial results for mevrometostat, an experimental drug aimed at metastatic castration-resistant prostate cancer (mCRPC). The findings indicate that when combined with standard hormone therapy, mevrometostat reduced disease progression rates by 50% and decreased the risk of death by 49% among patients previously treated with hormone therapy and chemotherapy.

Mevrometostat works by inhibiting enhancer of zeste homolog 2 (EZH2), an oncoprotein known to drive tumor progression by silencing tumor suppressor genes through histone methylation. Overexpression of EZH2 is linked to aggressive prostate cancer and poor prognosis, making it a compelling target for therapeutic intervention.

Despite its efficacy, common adverse effects in the trial included diarrhea (78%), decreased appetite (58.5%), and dysgeusia (58.5%), indicating the need for further safety evaluation. Trials are now moving forward with two Phase III trials (MEVPRO-1 and MEVPRO-2) to assess the full potential of mevrometostat in treating advanced prostate cancer.

If Phase III trials confirm its effectiveness, mevrometostat could become a new standard of care in prostate cancer therapy.

Source.